Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Total Liabilities (2021 - 2026)

HeartSciences' Total Liabilities history spans 6 years, with the latest figure at $4.9 million for Q1 2026.

  • For Q1 2026, Total Liabilities rose 25.15% year-over-year to $4.9 million; the TTM value through Jan 2026 reached $4.9 million, up 25.15%, while the annual FY2025 figure was $4.0 million, 83.81% up from the prior year.
  • Total Liabilities reached $4.9 million in Q1 2026 per HSCS's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $8.1 million in Q2 2022 to a low of $1.8 million in Q4 2025.
  • Average Total Liabilities over 5 years is $3.6 million, with a median of $3.7 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: crashed 62.47% in 2023, then soared 83.81% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $3.7 million in 2022, then grew by 8.95% to $4.0 million in 2023, then decreased by 6.41% to $3.8 million in 2024, then plummeted by 51.77% to $1.8 million in 2025, then skyrocketed by 170.31% to $4.9 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Total Liabilities are $4.9 million (Q1 2026), $1.8 million (Q4 2025), and $3.3 million (Q3 2025).